- Home
- SUGP vs TNXP Comparison
SUGP vs TNXP Comparison
Compare SUGP & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUGP
- TNXP
- Stock Information
- Founded
- SUGP 1998
- TNXP 2007
- Country
- SUGP Hong Kong
- TNXP United States
- Employees
- SUGP N/A
- TNXP N/A
- Industry
- SUGP
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- SUGP
- TNXP Health Care
- Exchange
- SUGP NYSE
- TNXP Nasdaq
- Market Cap
- SUGP 20.3M
- TNXP 19.5M
- IPO Year
- SUGP 2024
- TNXP N/A
- Fundamental
- Price
- SUGP $1.74
- TNXP $0.13
- Analyst Decision
- SUGP
- TNXP Strong Buy
- Analyst Count
- SUGP 0
- TNXP 2
- Target Price
- SUGP N/A
- TNXP $53.50
- AVG Volume (30 Days)
- SUGP 1.6M
- TNXP 13.8M
- Earning Date
- SUGP 11-26-2024
- TNXP 11-12-2024
- Dividend Yield
- SUGP N/A
- TNXP N/A
- EPS Growth
- SUGP N/A
- TNXP N/A
- EPS
- SUGP 0.10
- TNXP N/A
- Revenue
- SUGP $20,252,232.00
- TNXP $11,291,000.00
- Revenue This Year
- SUGP N/A
- TNXP $62.53
- Revenue Next Year
- SUGP N/A
- TNXP $26.17
- P/E Ratio
- SUGP $16.96
- TNXP N/A
- Revenue Growth
- SUGP N/A
- TNXP 183.05
- 52 Week Low
- SUGP $0.98
- TNXP $0.12
- 52 Week High
- SUGP $5.86
- TNXP $22.08
- Technical
- Relative Strength Index (RSI)
- SUGP 56.59
- TNXP 33.87
- Support Level
- SUGP $1.07
- TNXP $0.13
- Resistance Level
- SUGP $1.20
- TNXP $0.15
- Average True Range (ATR)
- SUGP 0.27
- TNXP 0.01
- MACD
- SUGP 0.09
- TNXP 0.00
- Stochastic Oscillator
- SUGP 44.16
- TNXP 4.86
About SUGP SU GROUP HLDGS LTD
SU Group Holdings Ltd and its subsidiaries is an integrated security-related services company. The company has two reportable segments: security-related engineering services, and security guarding and screening services and related vocational training services. The company generates the majority of its revenue from the security-related engineering services segment.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.